DARA BioSciences (DARA) Makes David Drutz Permanent CEO; Steve Gorlin Appointed to Board
Tweet
Share
E-mailGet Alerts DARA Hot Sheet
Join SI Premium – FREE
DARA BioSciences, Inc. (Nasdaq: DARA) reported today that Steve Gorlin has been appointed to fill a vacancy on the Company's Board of Directors. Mr. Gorlin will serve as Chairman of the Board of Directors and will also serve on the Company's Audit, Compensation and Corporate Governance and Nominating Committees.
Mr. Gorlin was a founder of DARA and previously served as a member of the Board of Directors. Mr. Gorlin currently serves as Chairman and CEO of DemeRx, Inc., Chairman of NTC China, Inc., and Vice Chairman of MiMedx, Inc. (OTCBB:MDXG.OB). Mr. Gorlin formerly served as a founder and director of Hycor Biomedical, Inc. (which was acquired by Agilent), Theragencis Corporation, CytRx Corporation, Medicis Pharmaceutical Corporation, EntreMed, Inc., Medivation, Inc., and MRI Interventions, Inc. From 1998 to 2003, Mr. Gorlin served on the Business Advisory Council to The Johns Hopkins School of Medicine and currently sits on the board of The Johns Hopkins Alliance for Science and Technology Development, The Johns Hopkins BioMedical Engineering Advisory Board, and on the board of the Andrews Institute. Mr. Gorlin was re-appointed to the Company's Board of Directors to fill a vacancy created by Richard Franco's retirement.
Additionally, the Company reported today the approval by the Board of Directors of a change to the title of David J. Drutz. Dr. Drutz' title at the Company has been changed from "Interim Chief Executive Officer" to "President and Chief Executive Officer."
Mr. Gorlin was a founder of DARA and previously served as a member of the Board of Directors. Mr. Gorlin currently serves as Chairman and CEO of DemeRx, Inc., Chairman of NTC China, Inc., and Vice Chairman of MiMedx, Inc. (OTCBB:MDXG.OB). Mr. Gorlin formerly served as a founder and director of Hycor Biomedical, Inc. (which was acquired by Agilent), Theragencis Corporation, CytRx Corporation, Medicis Pharmaceutical Corporation, EntreMed, Inc., Medivation, Inc., and MRI Interventions, Inc. From 1998 to 2003, Mr. Gorlin served on the Business Advisory Council to The Johns Hopkins School of Medicine and currently sits on the board of The Johns Hopkins Alliance for Science and Technology Development, The Johns Hopkins BioMedical Engineering Advisory Board, and on the board of the Andrews Institute. Mr. Gorlin was re-appointed to the Company's Board of Directors to fill a vacancy created by Richard Franco's retirement.
Additionally, the Company reported today the approval by the Board of Directors of a change to the title of David J. Drutz. Dr. Drutz' title at the Company has been changed from "Interim Chief Executive Officer" to "President and Chief Executive Officer."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Balfour Beatty names Sarah Brand VP of Tampa buildings ops
- Nu Skin EVP of global sales takes medical leave
Create E-mail Alert Related Categories
Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
